4/A: CFO Kline Amends SEC Filing on Stock Option Exercise

Globus Medical CFO Kyle Kline filed an amended Form 4 to correct the number of stock options exercised from 5,000 to 4,896 shares of Class A Common Stock.

Summary

• Kyle Kline, Senior Vice President and CFO of Globus Medical Inc. (GMED), filed an amended Form 4.
• The amendment corrects an inadvertent error in a previous Form 4 filing dated December 3, 2025.
• The original filing incorrectly reported the exercise of 5,000 stock options.
• The corrected filing accurately states that 4,896 stock options were exercised.
• These options were exercised at a price of $63.68 per share.
• The exercise occurred prior to the sale of 4,896 shares of the issuer's Class A Common Stock.
• The options were granted on January 27, 2022, and vest over a four-year period, with one-fourth vesting on January 1, 2023, and the remainder vesting ratably monthly over the subsequent 36 months.
• Following the reported transaction, 104 derivative securities (stock options) are beneficially owned directly by Mr. Kline.

Sentiment

Score: 5

Explanation: This filing is an administrative correction of an insider transaction and does not reflect on the company's operational or financial performance, thus maintaining a neutral sentiment.

Future Outlook

This administrative filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• On December 3, 2025, the reporting person filed a Form 4 which inadvertently reported in Table II that 5,000 options were exercised prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock that was reported in Table I. As correctly reported in this amendment, the reporting person exercised 4,896 options prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock.

Industry Context

This filing is an administrative correction of an insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minor impact due to the correction of insider transaction details, ensuring the accuracy of public record regarding executive stock ownership and transactions.
• Regulatory Authorities: Ensures compliance with SEC reporting requirements for insider transactions.

Key Dates

Keywords

Globus Medical, GMED, Kyle Kline, CFO, Form 4, SEC filing, stock options, insider transaction, amendment, Class A Common Stock